Lexaria BioscienceLEXX
LEXX
About: Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.
Employees: 7
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
300% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 2
1.51% more ownership
Funds ownership: 6.75% [Q3] → 8.26% (+1.51%) [Q4]
7% less capital invested
Capital invested by funds: $3.25M [Q3] → $3.03M (-$224K) [Q4]
7% less funds holding
Funds holding: 27 [Q3] → 25 (-2) [Q4]
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$7
407%
upside
Avg. target
$7
407%
upside
High target
$7
407%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Yi Chen 27% 1-year accuracy 47 / 173 met price target | 407%upside $7 | Buy Maintained | 24 Jan 2025 |
Financial journalist opinion
Based on 3 articles about LEXX published over the past 30 days
Neutral
Accesswire
2 weeks ago
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / April 3, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide this progress update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study") underway in Australia. Enrollment of patients for all 5 Study arms has now been completed on schedule.
Neutral
TheNewswire
2 weeks ago
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss Kelowna, British Columbia – April 3, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to provide this progress update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the “ Study ”) underway in Australia.
Neutral
Accesswire
2 weeks ago
Lexaria's Human GLP-1 Study #5 Begins Dosing
Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide Study will investigate Pharmacokinetics and Safety KELOWNA, BC / ACCESS Newswire / April 2, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that dosing has begun as scheduled in its human study GLP-1-H25-5 (the "Study") that is comparing oral DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide. On November 20, 2024, Lexaria reported on an earlier 12-week study in rodents which showed that with unlimited food available, oral DehydraTECH-liraglutide demonstrated a 5.88% weight reduction and an 11.54% blood sugar reduction as compared to baseline.
Neutral
Accesswire
1 month ago
Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)
More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound® As previously announced, oral DehydraTECH-tirzepatide also reduced adverse events by 47% compared to injected Zepbound® Lexaria's oral capsules worthy of expanded investigation as a viable alternative to injected tirzepatide. KELOWNA, BC / ACCESS Newswire / March 18, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce positive pharmacokinetic ("PK") results from Human Study #3 or GLP-1-H24-3 (the "Study"), comparing an oral version of DehydraTECH-processed Zepbound® ("DehydraTECH-tirzepatide") to conventional injected Zepbound®.
Neutral
TheNewswire
1 month ago
Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound
More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound As previously announced, oral DehydraTECH-tirzepatide also reduced adverse events by 47% compared to injected Zepbound
Neutral
TheNewswire
1 month ago
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
Lexaria executing a triple-pronged strategy in obesity and diabetes Semaglutide recently approved to treat chronic kidney disease
Neutral
Accesswire
1 month ago
The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
Lexaria executing a triple-pronged strategy in obesity and diabetes Semaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") strategic update. Lexaria is rapidly executing its multi-faceted strategy centered around its proprietary DehydraTECH processing technology.
Neutral
Accesswire
1 month ago
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
5th study arm in 12-week Phase 1b Study receives lead clinical site approval KELOWNA, BC / ACCESS Newswire / February 24, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee ("HREC") approval that was required before dosing can begin in the 5th study arm of the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the "Study") in Australia. This news complements similar news issued on November 13, 2024, when initial lead clinical site HREC approval was received for the first 4 arms of the Study.
Neutral
TheNewswire
1 month ago
Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm
5 th study arm in 12-week Phase 1b Study receives lead clinical site approval Kelowna, British Columbia – February 24, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces it has received lead clinical site human research ethics committee (“HREC” ) approval that was required before dosing can begin in the 5 th study arm of the Company's Phase 1b, 12-week chronic study GLP-1-H24-4, (the “ Study ”) in Australia.
Neutral
TheNewswire
1 month ago
Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide
Pursuing the world's first-ever orally-dosed liraglutide Kelowna, British Columbia – February 20, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, announces that it has made a strategic business decision to further investigate the commercial opportunities and applications for a unique new GLP-1 solution: orally taken liraglutide processed with our wholly-owned DehydraTECH™ enhancement technology.
Charts implemented using Lightweight Charts™